• We use the most widely used colon 26 cachexia animal model
• We inject the tumor cells to mice and closely follow performance
• We have much stricter standard to perform efficacy study:

1. 1. Other studies treat mice as a group despite not all develop cachexia
   2. We treat mice individualized(only treat mice with cachexia onset)
   3. We adopt same enrollment criteria and efficacy endpoints as patients

• Our goal is to make sure the efficacy could be clinically translational
• Below is the second study we have performed with Cachexinol™

This curve only shows the efficacy  of CELLg8®  formula (0.5mg) in the improvement of survival. This confirms the significant efficacy of CELLg8®  formula observed in study 1

• Three dosages of Cachexinol™ formula were tested:

1. 1. 1.  0.25mg
      2. 0.5mg
      3. 1mg

• Mice treated P.O. with Cachexilnol™ every other day
• Mice body weight and health condition was monitored daily

Three different doses of Cachexilnol™ (standardized to mg of ) were given orally to mice after cachexia onset. Mice body weight (Mean±SEM) of each group was shown above. The efficacy of two high doses(0.5mg and 1mg) is obviously better than the 0.25mg dose.

• Cachexinol™ formula is very effective to treat cancer cachexia and reduce cancer mortality.
• What is critical for clinical success of Cachexinol™ formula is to determine right patients(right indication/right clinical scenario) and right dose with right dosing schedule.
• Cachexinol was shown to rebound weight in subjects.